{"id":"pembrolizumab-sc","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"3-5","effect":"Immune-mediated pneumonitis"},{"rate":"2-4","effect":"Immune-mediated colitis"},{"rate":"1-3","effect":"Immune-mediated hepatitis"},{"rate":"5-10","effect":"Immune-mediated thyroiditis"},{"rate":"10-15","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pembrolizumab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed on tumor cells and immune cells. This blockade releases the brakes on the immune system, restoring T-cell proliferation, activation, and anti-tumor function. The subcutaneous (SC) formulation provides an alternative to intravenous administration with improved patient convenience.","oneSentence":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:31.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (NSCLC)"},{"name":"Melanoma"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Urothelial carcinoma"},{"name":"Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors"}]},"trialDetails":[{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":1301},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT03030378","phase":"PHASE1","title":"Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-30","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":36},{"nctId":"NCT04708418","phase":"PHASE2","title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-15","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","enrollment":60},{"nctId":"NCT04919629","phase":"PHASE2","title":"APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-04-27","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":60},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT07217496","phase":"PHASE1","title":"N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer","status":"WITHDRAWN","sponsor":"Vadim S Koshkin","startDate":"2026-02-15","conditions":"Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":""},{"nctId":"NCT06894771","phase":"PHASE1","title":"A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-23","conditions":"Malignant Neoplasm","enrollment":5},{"nctId":"NCT06385080","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":287},{"nctId":"NCT05843448","phase":"PHASE1","title":"IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-04-19","conditions":"High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT05269381","phase":"PHASE1, PHASE2","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-03-31","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":132},{"nctId":"NCT07431827","phase":"PHASE3","title":"MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04219254","phase":"PHASE1, PHASE2","title":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BioInvent International AB","startDate":"2020-06-29","conditions":"Solid Tumor, Adult","enrollment":197},{"nctId":"NCT06041802","phase":"PHASE2","title":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-10-20","conditions":"Squamous Cell Carcinoma","enrollment":19},{"nctId":"NCT05493566","phase":"EARLY_PHASE1","title":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-11-01","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":15},{"nctId":"NCT05232851","phase":"PHASE1, PHASE2","title":"A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-06-16","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma","enrollment":20},{"nctId":"NCT06698042","phase":"PHASE3","title":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-21","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":67},{"nctId":"NCT06504394","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-14","conditions":"Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent","enrollment":66},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT02600949","phase":"PHASE1","title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-11","conditions":"Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":117},{"nctId":"NCT02432963","phase":"PHASE1","title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-06-14","conditions":"Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma","enrollment":11},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT05307874","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ImCheck Therapeutics","startDate":"2022-05-04","conditions":"Solid Tumor, Adult","enrollment":56},{"nctId":"NCT06790966","phase":"PHASE3","title":"Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDS Biotechnology Corp.","startDate":"2025-05-30","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":351},{"nctId":"NCT03260504","phase":"PHASE1","title":"Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-08-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer","enrollment":6},{"nctId":"NCT05256381","phase":"PHASE2","title":"A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2022-06-21","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma","enrollment":166},{"nctId":"NCT05514990","phase":"PHASE1, PHASE2","title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-10-07","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":10},{"nctId":"NCT06157151","phase":"PHASE2","title":"PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Precigen, Inc","startDate":"2025-03-21","conditions":"Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy","enrollment":46},{"nctId":"NCT06212752","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-13","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":39},{"nctId":"NCT07223424","phase":"PHASE2","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","status":"RECRUITING","sponsor":"Diwakar Davar","startDate":"2025-11-04","conditions":"Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma","enrollment":480},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT05996523","phase":"PHASE2","title":"Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-07","conditions":"Oropharyngeal Squamous Cell Carcinoma (SCC)","enrollment":16},{"nctId":"NCT04383743","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-24","conditions":"Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma","enrollment":17},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05722015","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-14","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":377},{"nctId":"NCT04369937","phase":"PHASE2","title":"HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-07-06","conditions":"HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":18},{"nctId":"NCT03249792","phase":"PHASE1","title":"Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-09-20","conditions":"Solid Tumor, Lymphoma","enrollment":140},{"nctId":"NCT03113487","phase":"PHASE2","title":"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-02-01","conditions":"Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":29},{"nctId":"NCT05704985","phase":"PHASE1","title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"DEKA Biosciences","startDate":"2023-04-03","conditions":"Cancer, Solid Tumor, Colorectal Cancer","enrollment":39},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT04633278","phase":"PHASE2","title":"CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-01-21","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":24},{"nctId":"NCT06099782","phase":"PHASE2","title":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-26","conditions":"Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma","enrollment":147},{"nctId":"NCT04907851","phase":"PHASE2","title":"A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-12-10","conditions":"Advanced Solid Tumours","enrollment":45},{"nctId":"NCT03747484","phase":"PHASE1, PHASE2","title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-03","conditions":"Other Skin","enrollment":7},{"nctId":"NCT02907099","phase":"PHASE2","title":"Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":20},{"nctId":"NCT03665597","phase":"PHASE1","title":"Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-19","conditions":"Melanoma","enrollment":138},{"nctId":"NCT02500576","phase":"PHASE2","title":"Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-07","conditions":"Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7","enrollment":18},{"nctId":"NCT05207722","phase":"PHASE1, PHASE2","title":"CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma","status":"TERMINATED","sponsor":"Celularity Incorporated","startDate":"2022-04-14","conditions":"Metastatic HER2 Positive Gastroesophageal Junction Cancer","enrollment":1},{"nctId":"NCT04956692","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-05","conditions":"Non-Small Cell Lung Cancer","enrollment":531},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT03761914","phase":"PHASE1, PHASE2","title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2019-09-30","conditions":"Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer","enrollment":26},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT04787042","phase":"PHASE1, PHASE2","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","status":"RECRUITING","sponsor":"Simcha IL-18, Inc.","startDate":"2021-08-06","conditions":"Cancer, Solid Tumor, Melanoma","enrollment":316},{"nctId":"NCT05382325","phase":"PHASE1","title":"A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-06-16","conditions":"Advanced or Metastatic Solid Tumors","enrollment":70},{"nctId":"NCT05898763","phase":"PHASE1, PHASE2","title":"TEIPP Immunotherapy in Patients With NSCLC","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2021-09-29","conditions":"Non Small Cell Lung Cancer","enrollment":26},{"nctId":"NCT02826486","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2016-09","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":80},{"nctId":"NCT05077709","phase":"PHASE2","title":"IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"IO Biotech","startDate":"2022-02-14","conditions":"Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT05101356","phase":"PHASE1, PHASE2","title":"A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma","status":"RECRUITING","sponsor":"Tianhong Li","startDate":"2021-10-13","conditions":"Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma","enrollment":77},{"nctId":"NCT03639948","phase":"PHASE2","title":"Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2018-09-04","conditions":"Triple-negative Breast Cancer","enrollment":120},{"nctId":"NCT03861793","phase":"PHASE1, PHASE2","title":"A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)","status":"COMPLETED","sponsor":"Mural Oncology, Inc","startDate":"2019-02-26","conditions":"Advanced Solid Tumors","enrollment":116},{"nctId":"NCT02901899","phase":"PHASE2","title":"Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-11-11","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":45},{"nctId":"NCT04294576","phase":"PHASE1","title":"Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"BJ Bioscience, Inc.","startDate":"2019-12-04","conditions":"Locally Advanced/Metastatic Solid Tumors","enrollment":92},{"nctId":"NCT03063632","phase":"PHASE2","title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-12-14","conditions":"Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma","enrollment":28},{"nctId":"NCT02376699","phase":"PHASE1","title":"Safety Study of SEA-CD40 in Cancer Patients","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2015-02-28","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease","enrollment":159},{"nctId":"NCT04920617","phase":"PHASE2","title":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","startDate":"2021-06-18","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":102},{"nctId":"NCT03280667","phase":"PHASE2","title":"Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2017-12-12","conditions":"Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer","enrollment":59},{"nctId":"NCT03918499","phase":"PHASE1, PHASE2","title":"IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2019-04-19","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8","enrollment":9},{"nctId":"NCT03094637","phase":"PHASE2","title":"Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-06","conditions":"High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome","enrollment":40},{"nctId":"NCT02990845","phase":"PHASE1, PHASE2","title":"Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2017-09-15","conditions":"Premenopausal Breast Cancer","enrollment":16},{"nctId":"NCT01993719","phase":"PHASE2","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-12","conditions":"Metastatic Melanoma","enrollment":33},{"nctId":"NCT02089685","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":"Renal Cell Carcinoma, Melanoma","enrollment":295},{"nctId":"NCT03084640","phase":"PHASE1","title":"Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-05-04","conditions":"Malignant Melanoma","enrollment":30},{"nctId":"NCT03562871","phase":"PHASE1, PHASE2","title":"IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC","status":"COMPLETED","sponsor":"IO Biotech","startDate":"2018-08-22","conditions":"NSCLC","enrollment":109},{"nctId":"NCT05234606","phase":"PHASE1, PHASE2","title":"A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"Silverback Therapeutics","startDate":"2022-03","conditions":"Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02703714","phase":"PHASE2","title":"Pembrolizumab and GM-CSF in Biliary Cancer","status":"COMPLETED","sponsor":"Robin Kate Kelley","startDate":"2016-05-06","conditions":"Biliary Cancer","enrollment":42},{"nctId":"NCT02489357","phase":"NA","title":"Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-12-11","conditions":"Stage IV Prostate Cancer","enrollment":12},{"nctId":"NCT02757391","phase":"PHASE1","title":"CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-09","conditions":"Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma","enrollment":1},{"nctId":"NCT04058964","phase":"PHASE2","title":"Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-02-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pembrolizumab SC","genericName":"Pembrolizumab SC","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells. Used for Metastatic non-small cell lung cancer (NSCLC), Melanoma, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}